News & Updates

Show Multimedia Only
More evidence supports enzalutamide’s link with poorer mood and cognitive outcomes in mCRPC

More evidence supports enzalutamide’s link with poorer mood and cognitive outcomes in mCRPC

09 May 2024 byKanas Chan

Patients with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide reported more fatigue, depression and deterioration in perceived cognitive ability, and slower reaction time than those receiving abiraterone acetate, according to results of the ACE study.

09 May 2024
Long-term lecanemab reduces cognitive decline in early AD

Long-term lecanemab reduces cognitive decline in early AD

30 Apr 2024 byStephen Padilla

Treatment with lecanemab continue to provide benefits to patients with early Alzheimer’s disease (AD) through 24 months, according to the results of the ongoing open-label extension study of Clarity AD. Those who have been treated much later also show disease improvements.

30 Apr 2024